How much funding has Etana Biotechnologies raised?

Etana Biotechnologies has raised $8.0M in total funding, most recently a Series B round.

Who are Etana Biotechnologies's investors?

Etana Biotechnologies's investors include DEG, Yunfeng Capital, HighLight Capital, East Ventures.

When was Etana Biotechnologies founded?

Etana Biotechnologies was founded in 2014.

Where is Etana Biotechnologies headquartered?

Etana Biotechnologies is headquartered in Jakarta, Indonesia.

What industry is Etana Biotechnologies in?

Etana Biotechnologies operates in Biotech, Healthcare.

How many employees does Etana Biotechnologies have?

Etana Biotechnologies has 51-200 employees.

Etana Biotechnologies

High-quality, affordable and innovative biopharmaceuticals for Indonesia

Jakarta, Indonesia · Founded 2014 · $8.0M raised

Biotech

Healthcare

Headquarters: Jakarta
Employees: 51–200
Founded: 2014
Business Model: B2B

Website: id.etanabiotech.com
Total Funding: $8.0M
Last Round: $8.0M Series BMar 2023
Rounds: 1

About

PT Etana Biotechnologies Indonesia (Etana) is an Indonesian biopharmaceutical company established in 2014, focused on manufacturing, research and development, and marketing of high-quality, affordable, and innovative biologics. The company specializes in recombinant gene technology, monoclonal antibodies (MABs), and vaccine production, targeting oncology and infectious disease treatment areas. Etana has been officially designated as a Center of Excellence for Vaccine and Biotechnology by Indonesia's Ministry of Health, and has secured investment from DEG (Deutsche Investitions- und Entwicklungsgesellschaft) to fund its oncology pipeline. The company maintains strategic partnerships with global biopharmaceutical firms including CanSinoBio and DEG Impulse for digital transformation of vaccine production.

Summary

Etana Biotechnologies is a Biotech company based in Jakarta, Indonesia, founded in 2014. It has raised $8.0M in total across 1 round, most recently a $8.0M Series B round in Mar 2023. Investors include DEG, Yunfeng Capital and HighLight Capital.